These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 34244768)

  • 1. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.
    Abdelnabi R; Foo CS; De Jonghe S; Maes P; Weynand B; Neyts J
    J Infect Dis; 2021 Sep; 224(5):749-753. PubMed ID: 34244768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of molnupiravir and interferon for the treatment of SARS-CoV-2 in golden Syrian hamster.
    Liu D; Leung KY; Zhang R; Lam HY; Fan Y; Xie X; Chan KH; Hung IF
    J Med Virol; 2024 Sep; 96(9):e29901. PubMed ID: 39210614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of therapeutic antibody efficacy against multiple SARS-CoV-2 variants in the hamster model.
    Cong Y; Dixit S; Perry DL; Huzella LM; Kollins E; Byrum R; Anthony SM; Drawbaugh D; Lembirik S; Postnikova E; Eaton B; Murphy M; Kocher G; Hadley K; Marketon AE; Bernbaum RM; Hischak AMW; Hart R; Vaughan N; Wada J; Qin J; St Claire MC; Schmaljohn CS; Holbrook MR
    Antiviral Res; 2024 Oct; 230():105987. PubMed ID: 39147143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
    Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y
    Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35579953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study.
    Fountain-Jones NM; Vanhaeften R; Williamson J; Maskell J; Chua IJ; Charleston M; Cooley L
    Lancet Microbe; 2024 May; 5(5):e452-e458. PubMed ID: 38527471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
    Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
    EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.
    Sanderson T; Hisner R; Donovan-Banfield I; Hartman H; Løchen A; Peacock TP; Ruis C
    Nature; 2023 Nov; 623(7987):594-600. PubMed ID: 37748513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
    Kabinger F; Stiller C; Schmitzová J; Dienemann C; Kokic G; Hillen HS; Höbartner C; Cramer P
    Nat Struct Mol Biol; 2021 Sep; 28(9):740-746. PubMed ID: 34381216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model.
    Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Smith MK; Sticher ZM; Kalykhalov AA; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK
    Nat Commun; 2022 Jul; 13(1):4416. PubMed ID: 35906230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
    Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
    J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro.
    Liu D; Leung KY; Lam HY; Zhang R; Fan Y; Xie X; Chan KH; Hung IF
    Virus Res; 2024 Jul; 345():199371. PubMed ID: 38621598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
    Bai Y; Shen M; Zhang L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.
    Fröba M; Große M; Setz C; Rauch P; Auth J; Spanaus L; Münch J; Ruetalo N; Schindler M; Morokutti-Kurz M; Graf P; Prieschl-Grassauer E; Grassauer A; Schubert U
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel SARS-CoV-2 variants: the pandemics within the pandemic.
    Boehm E; Kronig I; Neher RA; Eckerle I; Vetter P; Kaiser L;
    Clin Microbiol Infect; 2021 Aug; 27(8):1109-1117. PubMed ID: 34015535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants.
    Rosales R; McGovern BL; Rodriguez ML; Leiva-Rebollo R; Diaz-Tapia R; Benjamin J; Rai DK; Cardin RD; Anderson AS; ; Sordillo EM; van Bakel H; Simon V; García-Sastre A; White KM
    Antiviral Res; 2024 Oct; 230():105970. PubMed ID: 39067667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.